Bird
Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?
Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research
Trump Nominates Renowned Surgeon Martin Makary as FDA Commissioner
Martin Makary, FDA Commissioner, Donald Trump, Johns Hopkins, Surgeon, Nomination
Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates
Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination
Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections
Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow
Amazon One Medical Introduces AI Tools to Enhance Primary Care Experience
Amazon One Medical, AI tools, primary care, healthcare technology, generative AI, patient care, administrative workload
Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes
Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry
Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results
Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601
Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial
Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules